ArticlemAbs
A new class of bispecific antibodies to redirect T cells for cancer immunotherapy.
Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 37 citations in OpenAlex.
- Extracellular vesicles in spine tumors: biological roles, immune modulation, and therapeutic implications.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2026Review
- Emerging strategies and novel therapeutic targets in acute myeloid leukemia: current advances and future directions.Biomarker research · 2025Review
- Trop2-Targeted Molecular Imaging in Solid Tumors: Current Advances and Future Outlook.Molecular pharmaceutics · 2024Review
- The Evolving Role of Bispecific Antibodies in Diffuse Large B-Cell Lymphoma.Journal of personalized medicine · 2024Review
- A Novel bispecific T-cell engager (BiTE) targeting CD22 and CD3 has both in vitro and in vivo activity and synergizes with blinatumomab in an acute lymphoblastic leukemia (ALL) tumor model.Cancer immunology, immunotherapy : CII · 2023Article
- A literature review of the promising future ofAnnals of translational medicine · 2022Review
- Immunotherapy in Acute Myeloid Leukemia: Where We Stand.Frontiers in oncology · 2021Review
- An Update on Immune Based Therapies in Acute Myeloid Leukemia: 2021 and Beyond!Advances in experimental medicine and biology · 2021Article
- Biology drives the discovery of bispecific antibodies as innovative therapeutics.Antibody therapeutics · 2020Review
- Design Principles for Bispecific IgGs, Opportunities and Pitfalls of Artificial Disulfide Bonds.Antibodies (Basel, Switzerland) · 2018Article
- The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target.Oncotarget · 2018Review
- T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics.Pharmacology & therapeutics · 2018Review
- Bispecific antibodies: design, therapy, perspectives.Drug design, development and therapy · 2018Review
- Article
- Article
- Antibody darts on target for acute myelogenous leukemia.Annals of translational medicine · 2017Article
- Antibody Therapeutics in Oncology.Immunotherapy (Los Angeles, Calif.) · 2016Article
- Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?Antibodies (Basel, Switzerland) · 2015Review
- Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody.Oncoimmunology · 2015Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Various constructs of bispecific antibodies (bsAbs) to redirect effector T cells for the targeted killing of tumor cells have shown considerable promise in both preclinical and clinical studies. The single-chain variable fragment (scFv)-based formats, including bispecific T-cell engager (BiTE) and dual-affinity re-targeting (DART), which provide monovalent binding to both CD3 on T cells and to the target antigen on tumor cells, can exhibit rapid blood clearance and neurological toxicity due to their small size (~55 kDa). Herein, we describe the generation, by the modular DOCK-AND-LOCK™) (DNL™) method, of novel T-cell redirecting bispecific antibodies, each comprising a monovalent anti-CD3 scFv covalently conjugated to a stabilized dimer of different anti-tumor Fabs. The potential advantages of this design include bivalent binding to tumor cells, a larger size (~130 kDa) to preclude renal clearance and penetration of the blood-brain barrier, and potent T-cell mediated cytotoxicity. These prototypes were purified to near homogeneity, and representative constructs were shown to provoke the formation of immunological synapses between T cells and their target tumor cells in vitro, resulting in T-cell activation and proliferation, as well as potent T-cell mediated anti-tumor activity. In addition, in vivo studies in NOD/SCID mice bearing Raji Burkitt lymphoma or Capan-1 pancreatic carcinoma indicated statistically significant inhibition of tumor growth compared with untreated controls.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.